Dear Dr. Reit:

Please refer to your supplemental new drug application dated March 20, 2001, received March 21, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Prandin® (repaglinide) Tablets.

We acknowledge receipt of your submissions dated April 18, 2001, and January 16, 2002.

This supplemental new drug application provides for changes to the package insert, including but not limited to:

1. Revisions to the CLINICAL PHARMACOLOGY section:
   (a) Modification to the Drug-Drug Interactions subsection.
   (b) Modification to the Special Populations subsection.
2. Deletion of Special Warning in Increased Risk of Cardiac Mortality, located in the CONTRAINDICATIONS section
4. Revisions to the PRECAUTIONS section, Drug-Drug Interactions subsection.
5. Revision to the ADVERSE REACTIONS section, Infrequent Adverse Events subsection, to include several rare, spontaneously reported post-marketing adverse events.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert). Please note that 21 CFR 201.56(e) requires that final printed labeling must contain the date of the most recent revision of the labeling, identified as such, placed prominently immediately after the last section of the labeling. We also recommend that you include a unique identifier.

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA (January 1999).
Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-741/S-012." Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call James Cross, Regulatory Project Manager, at 301-827-6381.

Sincerely,

David G. Orloff, M.D.  
Director  
Division of Metabolic and Endocrine Drug Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research